For Women Managing Nighttime Incontinence, Better Sleep and Comfort Start with BD® PureWick® Urine Collection System
Rhea-AI Summary
BD (NYSE: BDX) announced new clinical findings (April 9, 2026) showing the PureWick® Urine Collection System helped women with nighttime urinary incontinence report better sleep, greater comfort, and ease of use.
In a four-week randomized trial of 165 women across 13 U.S. sites, ~70% said they would continue using PureWick®; study noted low skin irritation and effective urine capture.
Positive
- Randomized trial of 165 women over four weeks
- ~70% of participants would like to continue using PureWick®
- Improved sleep and reported quality-of-life benefits
- Low incidence of skin irritation reported
- Safe and effective urine capture in home setting
- Designed to reduce nighttime bed exits and fall risk
Negative
- None.
News Market Reaction – BDX
In the Apr 9 session, BDX declined 1.04%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Monitoring product launch | Positive | -0.2% | Introduced HemoSphere Stream module for continuous, noninvasive arterial waveform monitoring. |
| Apr 01 | AI dispensing launch | Positive | -0.6% | Launched AI-enabled Pyxis Pro and Incada analytics platforms across European hospitals. |
| Mar 02 | FDA 510(k) clearance | Positive | +0.0% | Received FDA 510(k) clearance for Surgiphor 1000mL antimicrobial irrigation system. |
| Feb 25 | Tender offer pricing | Neutral | -2.4% | Announced pricing and accepted amounts for up to $2B senior note tenders. |
| Feb 25 | Tender upsizing | Neutral | -0.8% | Upsized Aggregate Offer Cap and sub-cap for long-dated senior notes tender offers. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent product and technology launches with seemingly positive tone often saw flat-to-negative next-day moves, while liability-management announcements drew more pronounced declines.
Over the last few months, BD has focused on product innovation and balance sheet actions. On Apr 7, it launched the HemoSphere Stream Module for noninvasive blood pressure insight, and on Apr 1 it introduced AI-enabled medication dispensing in Europe. Earlier, on Mar 2, BD secured FDA 510(k) clearance for Surgiphor 1000mL. In late February, it upsized and priced up to $2,000,000,000 of note tender offers. Today’s PureWick study news fits the pattern of patient-focused product updates.
Key Terms
urinary incontinence medical
female external catheter medical
randomized trial medical
non-invasive medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New study findings published in the Journal of Clinical Medicine highlight the ease of use and comfort of BD PureWick® Female External Catheter can support a better night's rest
FRANKLIN LAKES, N.J. , April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new clinical findings revealing that women managing nighttime urinary incontinence reported better sleep and greater overall comfort when using the BD PureWick® Urine Collection System. According to the study, published in the Journal of Clinical Medicine, participants highlighted the system's ease of use and the non-invasive design of the PureWick® Flex Female External Catheter as key factors in helping them rest more comfortably through the night.
Bladder leakage affects millions of people and can disrupt sleep, cause skin irritation and reduce confidence and independence — especially among older adults. The PureWick® Urine Collection System offers a gentle, non-invasive option designed to help users stay dry overnight without the need for internal catheters, frequent pad changes, or leaving the bed to go to the bathroom.
"The findings from this study demonstrate that the PureWick® Flex Female External Catheter can be integrated safely and comfortably into the home setting, giving many women a greater sense of independence and dignity," said Dr. Michael J Kennelly, Professor of Urology at Wake Forest School of Medicine. "Any innovation that helps reduce the daily burden of incontinence and supports quality of life represents an important step forward for our patients."
Study Highlights
In a four-week randomized trial of 165 women, the PureWick® Flex Female External Catheter was compared to a traditional female urinary pouch. Key findings include:
- Improved sleep and quality of life
- Safe and effective urine capture
- Easier to place and remove
- Low incidence of skin irritation
- Approximately
70% would like to continue using PureWick® External Catheters
"This study reinforces what we hear from women every day — that comfort, confidence and a good night's sleep have a direct impact on their quality of life," said Chris DelGiudice, vice president and general manager of Urology & Critical Care at BD. "With safety the top priority, the PureWick® Urine Collection System was designed to allow women with urinary incontinence to stay in bed comfortably, helping reduce trips to the bathroom which are associated with fall risk."
With most participants aged 65 and older, the results highlight the PureWick® Urine Collection System as an option for women who value independence and want to remain active in their own homes. The system uses a soft, flexible external absorbent material and gentle suction to draw away voided urine from the body into a collection canister, helping keep skin dry throughout the night.
Sponsored by BD and conducted across 13 clinical sites in
The PureWick® Urine Collection System is available at PureWickAtHome.com or by calling 1-800-323-0914.
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media | Investors |
Matt Marcus | Shawn Bevec |
View original content to download multimedia:https://www.prnewswire.com/news-releases/for-women-managing-nighttime-incontinence-better-sleep-and-comfort-start-with-bd-purewick-urine-collection-system-302737568.html
SOURCE BD (Becton, Dickinson and Company)